These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29454321)

  • 21. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
    Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
    J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
    Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
    Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
    Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
    Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of everolimus in metastatic urothelial cancer.
    Milowsky MI; Iyer G; Regazzi AM; Al-Ahmadie H; Gerst SR; Ostrovnaya I; Gellert LL; Kaplan R; Garcia-Grossman IR; Pendse D; Balar AV; Flaherty AM; Trout A; Solit DB; Bajorin DF
    BJU Int; 2013 Aug; 112(4):462-70. PubMed ID: 23551593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.
    Lee JB; Park HS; Park S; Lee HJ; Kwon KA; Choi YJ; Kim YJ; Nam CM; Cho NH; Kang B; Chung HC; Rha SY
    Cancer Res Treat; 2019 Oct; 51(4):1578-1588. PubMed ID: 30999721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
    Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
    Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen.
    De Luca R; Profita G; Vella M; Cicero G
    Oncology; 2019; 97(6):341-347. PubMed ID: 31461721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of temsirolimus in patients with metastatic breast cancer.
    Fleming GF; Ma CX; Huo D; Sattar H; Tretiakova M; Lin L; Hahn OM; Olopade FO; Nanda R; Hoffman PC; Naughton MJ; Pluard T; Conzen SD; Ellis MJ
    Breast Cancer Res Treat; 2012 Nov; 136(2):355-63. PubMed ID: 22245973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
    Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
    Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
    Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
    JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.